Search results
Results from the WOW.Com Content Network
Volume growth of Amgen's (AMGN) key drugs like Prolia, Kyprolis, Repatha and others and biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature ...
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
Top Research Reports for Amazon, Amgen & TOTAL
Volume growth from Amgen's (AMGN) key drugs like Prolia, Xgeva, Repatha and others is expected to have been partially offset by biosimilar/generic competition for mature drugs.
For premium support please call: 800-290-4726 more ways to reach us
Today's Research Daily features new research reports on 16 major stocks, including Amgen Inc. (AMGN), Altria Group, Inc. (MO), and Uber Technologies, Inc. (UBER).
Amgen's positive trial results update on its GLP-1 injectable for obesity, MariTide, sent its ... Lilly recorded a total of $2 billion from its GLP-1 products in 2023, while Novo Nordisk pocketed ...